论文部分内容阅读
投资是经济增长三大动力之一,非典时期也不例外。疫情高峰过后,中国各行各业为确保经济持续稳定增长,积极寻求投资亮点,拓宽投资领域,加大投资力度。非典时期中国企业投资力度最大的首推医药行业。4月初,白云山制药股份有限公司贷款3000万元建设抗非典药物基地;广州市医药公司申请抗非典流动资金贷款6000万元、买汇400万美元。从4月1日至5月20日的50天内,与抗非典相关的医药行业仅从中国工商银行就贷款79.1亿元,日均贷款近1.6亿元。与医药行业备受投资者关注的情形相比,在股市上表现得淋漓尽致的还有其他事关健康的产业。
Investment is one of the three major drivers of economic growth. SARS is no exception. After the outbreak of the epidemic, all walks of life in China actively sought investment highlights, broadened the investment areas and increased their investments to ensure sustained and steady economic growth. During the SARS period, the biggest investment in Chinese enterprises devaluation of the pharmaceutical industry. In early April, Baiyunshan Pharmaceutical Co., Ltd. made a loan of 30 million yuan to build an anti-SARS drug base. Guangzhou Pharmaceutical Co., Ltd. applied for a loan of 60 million yuan against the current capital of atypical pneumonia and purchased 4 million U.S. dollars. Within 50 days from April 1 to May 20, the pharmaceutical industry related to SARS only made loans of RMB7.91 billion from Industrial and Commercial Bank of China and average daily loans of nearly RMB160 million. There are other health-related industries that are most vividly represented in the stock market, compared to the much-anticipated pharmaceutical industry.